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Abstract 
Antiprothrombin antibodies have been proposed as potential new biomarkers for thrombosis and/or pregnancy 
morbidity in the setting of the antiphospholipid syndrome (APS). Antiprothrombin antibodies are commonly 
detected by ELISA, using prothrombin coated onto irradiated plates (aPT), or prothrombin in complex with 
phosphatidylserine (aPS/PT), as antigen. Although these antibodies can co-exist in the same 
patient, aPT and aPS/PT seem to belong to different populations of autoantibodies. Early research explored the role 
of antibodies to prothrombin as potential antigenic targets for the lupus anticoagulant (LA). To date their clinical 
significance is being investigated and their potential role in identifying patients at higher risk of developing 
thrombotic events or pregnancy morbidity is being probed. 
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Introduction 
Antiphospholipid antibodies (aPL) are immunoglobulins shown to be related to diverse clinical events, such as 
arterial and venous thrombosis, complications of pregnancy, livedo reticularis, valvular disease, neurologic 
disorders, and thrombocytopenia [1]. Despite their name, aPL are not directed against anionic phospholipids but are 
part of a large family of autoantibodies targeting phospholipid-binding plasma proteins or their complex with 
phospholipids [2]. 
The term antiphospholipid syndrome (APS) links thrombosis and/or pregnancy morbidity to persistently positive 
aPL. The APS is now recognised as one of the most common causes of acquired thrombophilia [3]. 
In clinical practice, anticardiolipin antibodies (aCL), anti-β2 glycoprotein I (aβ2GPI) antibodies and the lupus 
anticoagulant (LA) have been the most established tests for the diagnosis of APS [3]. The clinical utility of aPL 
assays for autoantibodies other than the routinely used is now under debate [4]. Indeed, current lines of research are 
examining the usefulness of testing for new aPL specificities in helping to identify APS in patients with thrombosis 
and/or pregnancy morbidity, particularly in those who are repeatedly negative for the currently used tests [5]. 
Moreover, non-criteria aPL tests, among those antiphrothrombin antibodies, are proposed to help in assessing the 
risk for both thrombosis and pregnancy morbidities in patients suspected of APS [6••]. 
Prothrombin, also known as clotting factor II, is a vitamin K–dependent proenzyme of 72 kD. It is synthesized in 
the liver as an inactive zymogen and exerts a procoagulant activity via a prothrombinase complex, triggering 
fibrinogen conversion to fibrin [7]. Prothrombin binds to negatively charged phospholipids through the vitamin K-
dependent carboxylation/gamma-carboxyglutamic domains, located in fragment 1 of the prothrombin molecule 
(Fig. 1). In 1959, Loeliger first reported prothrombin as a cofactor for a ‘circulating anticoagulant’ in one patient 
with hypoprothrombinemia [8]. After this first observation, several groups have explored the clinical association of 
antibodies directed to this protein with the clinical manifestation of APS. 
 
Antiprothrombin Antibodies: Immunological Features and Detection Methods 
Antibodies to prothrombin can be detected by ELISA using prothrombin coated onto irradiated plates (aPT) or the 
phosphatidylserine/prothrombin complex as antigen (aPS/PT) [9, 10]. Both aPT and aPS/PT have been showed to 
be associated with the clinical manifestation of APS. Although they seem to belong to different populations of 
autoantibodies, they can both be detected simultaneously in one patient [11]. 
Antiprothombin antibodies are human species-specific [12], but binding with bovine prothrombin has also been 
reported in some cases [13]. 
The recognition of prothrombin by the antibodies largely depends on the mode of presentation of the antigen in 
solid phase. Antibodies are unable to bind prothrombin when prothrombin is immobilized onto non-irradiated plates 
[9]. On the contrary, they bind when prothrombin is immobilized on a suitable anionic surface, adsorbed on 
gamma-irradiated plates or exposed to immobilized anionic phospholipids (Fig. 2). The behaviour of these 
antibodies in binding the antigen resembles that of anti-β2GPI antibodies. Human prothrombin undergoes a 
conformational change upon binding to phosphatidylserine-containing surfaces in the presence of calcium [14]. 
Prethrombin 1 and fragment 1 [15, 16] and fragment 1 + 2 [17] have been reported as potential antigens recognized 
by antiprothrombin antibodies, suggesting that the dominant epitopes are likely to be located near the phospholipid-
binding site of the prothrombin molecule. 
 
Antiprothrombin Antibodies and the Lupus Anticoagulant 
Prothrombin was first reported by Loeliger in 1959 [8] as a cofactor for LA. Bajaj et al. [18] were the first to 
identify antibodies that bound prothrombin without neutralising its coagulant activity in two cases of 
hypoprothrombinemia associated to LA positivity. The authors suggested that acquired hypoprothrombinemia-lupus 
anticoagulant syndrome resulted from rapid clearance from the circulation of prothrombin antigen–antibody 
complexes. Lupus anticoagulant-hypoprothrombinemia syndrome is a rare clinical entity that can occur in 
association with SLE, transient viral infections, drug reactions or even in healthy individuals [19]. It has been 
speculated that antibodies found in the presences of LA-associated hypoprothrombinemia may be high affinity, in 
contrast to those detected in APS in which patients have low affinity antibodies. This difference may determine the 
clinical presentation of thrombosis versus bleeding [20]. Edson et al. reported the presence of circulating 
prothrombin–aPT complexes in patients who tested positive for LA and had normal prothrombin levels [21]. Fleck 
et al. [22] subsequently confirmed that some aPT showed LA activity, and, in 1991, Bevers et al. [12] showed that 
prothrombin was required for expressing LA activity in 69 % of aCL depleted LA-positive plasma samples. 
Available data support the existence of two types of aPT, those with and those without LA activity [23]. Recently, 
Pengo and colleagues reported a significantly lower prevalence of aPT, when compared to aβ2GPI, in a cohort of 
patients with LA. No association with the clinical features of APS was reported for aPT [24]. In contrast, some 
studies have shown a strong correlation between aPS/PT and the LA [25] and the nature of this correlation is 
currently being investigated. Our group has recently shown that aPS/PT, either IgG or IgM are associated with 
thrombosis in patients with and without LA. In addition, LA and aPS/PT, individually, were found to be 
independent risk factors for thrombosis and pregnancy loss. 
 
Clinical Significance 
The association between APS and antibodies to prothrombin, detected either as aPT or aPS/PT, has been evaluated 
with contradictory results [23, 26–30, 31•]. 
Although no association between aPT and the risk of thrombosis was found in a previous meta-analysis [32], a more 
recent systematic review suggests that aPT and aPS/PT are risk factors for thrombotic events [33••]. These data are 
based on more than 7,000 patients and controls from 38 studies analysing aPT and 10 studies analysing aPS/PT. 
While both antibodies to prothrombin (aPT and aPS/PT) have been shown to increase the risk thrombosis [OR 2.3 
(95 % CI 1.72–3.5)], aPS/PT represent a stronger risk factor for both arterial and/or venous thrombosis when 
compared to aPT [OR 5.11 (95 % CI 4.2–6.3) vs. 1.82 (95 % CI 1.44–2.75), respectively]. 
Two prospective studies have shown that the presence of aPT is a predictor of first or recurrent thrombosis in aPL 
patients [34, 35]. Forastiero et al. studied a cohort of patients persistently positive for aCL and/or LA. The authors 
showed that aPT predicted a higher risk of thromboembolic events, mainly in those patients also positive for the LA 
[34]. In an inception cohort of 101 SLE patients longitudinally followed for 15 years, Bizzarro et al. showed IgG 
aPT as the most useful predictor for thrombosis in SLE patients [35]. 
The notion of aPL has evolved from aPL being considered as pure diagnostic markers to becoming recognised as 
risk factor for thrombosis. Most importantly, it appears that the risk of thrombosis progressively increases with the 
number of positive aPL tests. While this concept has already been described for the so-called “triple positivity” for 
aCL, anti-β2GPI and LA [36], quadruple positivity for LA, aCL, anti-β2GPI and aPT has been shown to confer a 
30-fold higher risk of thrombosis, much higher risk than with the former combination [34, 35]. 
Many reports have also shown the clinical utility of aPS/PT in the diagnosis of APS [9]. Early data from Atsumi et 
al. showed that the presence of aPS/PT conferred an odds ratio for APS of 3.6 in his large cohort of 265 Japanese 
patients with systemic autoimmune diseases [10]. Recently, Zigon et al. showed aPS/PT as the strongest 
independent risk factor for the presence of obstetric complications in a cohort of 156 patients with systemic 
autoimmune diseases [37]. Interestingly, while some studies support the association of aPS/PT with arterial 
thrombosis, mainly in the setting of ischemic/thrombotic cerebrovascular events [38, 39], Zigon et al. failed to 
confirm this association. Both IgG and IgM aPS/PT were only associated with venous thrombosis [37]. 
Sanfelippo et al. [40] measured aPS/PT in 728 patients suspected of having APS, in the absence of of aCL or anti-
β2GPI. Of the 728 tested samples, 41 had elevated levels of aPS/PT with thrombotic events occurring in 11 out of 
the 22 patients with accessible medical histories. Overall, these data support the notion that testing for aPS/PT in 
those negative for aCL, anti-β2GPI and the LA can contribute to the identification of APS in patients that may 
otherwise go undetected with current testing methods. 
The importance of aPS/PT as a diagnostic marker of APS was also recently reported by our group [31•]. In this 
study, we evaluated several possible aPL specificities combination in an attempt to establish the profile that would 
provide us with the best diagnostic accuracy. Testing for six aPL derived in 23 possible combinations of results. 
The profile including LA + anti-β2GPI + aPS/PT held the best diagnostic accuracy for APS as a whole and, 
individually, for each thrombosis and pregnancy loss [OR 3.73 (95 % CI 1.82–5.38); OR 3.75 (95 % CI 2.13–6.62) 
and OR 4.82 (95 % CI 2.17–10.72), respectively] and the best specificity when compared with all the other 
attainable combination of tests, including the current classification criteria profile. 
When systematically reviewing the topic [33••], we found 7 studies that directly compared aPT and aPS/PT and 
their OR for thrombosis in 1196 patients [5, 9, 41–44]. When analysed, aPS/PT was shown to be more strongly 
associated with thrombosis, both arterial and venous, than aPT. 
While evidence tends to support the importance of testing for antiprothrombin antibodies, particularly aPS/PT, in 
routine practice, methodological issues appertaining to all aPL are the subject of debate and concern. Future efforts 
of harmonisation of tests used to detect antibodies binding prothrombin are urgently needed. Potentially, the use of 
reference material for these, as well as all aPL detection, will aid in solving many of the problems caused by a lack 
of standardisation of aPL assays. 
 
aPT and aPS/PT and Scoring Systems 
Risk prediction models are becoming increasingly common in both medical research and clinical practice, due in 
part to the enhanced focus on individualised medicine [45]. Recently, three score systems have been formulated to 
quantify the risk of thrombosis/obstetric events in APS, aiming to help physicians to stratify patients according to 
risk [46–48]. Two of those scores include antibodies to prothrombin among the variables computed when assessing 
the risk for thrombosis or pregnancy morbidity [47, 48]. Otomo et al. [47] designed the “antiphospholipid score” 
(aPL-S) with the purpose of quantifying the risk based on the aPL profile. An algorithm was created based on 
multiple aPL assays, with each assay being assigned a different score weighted on the relative risk of having clinical 
manifestations of APS. In order to independently validate the aPL-S, we applied the proposed score system to a 
cohort of 211 consecutive SLE patients, proving that the aPL-S correlated with a history of thrombosis or 
pregnancy loss in our cohort, suggesting that the aPL-S is a suitable quantitative marker of APS [49]. 
Recently, we formulated an alternative score derived from the combination of independent risk factors for 
thrombosis and pregnancy loss in a large cohort of well-characterised SLE patients: the Global APS Score or 
GAPSS [48]. This score takes into account not only the aPL profile (criteria [3] and non-criteria aPL [31•]) but also 
includes the conventional cardiovascular risk factors and the autoimmune antibodies profile [48] into the equation 
(Table 1). Positivity for aPS/PT was found to be an important variable when assessing the risk by using the GAPSS, 
suggesting that the addition of these antibodies can help in predicting APS-related clinical manifestations risk. The 
GAPSS scoring system is derived from the combination of independent risk for both thrombosis and pregnancy 
loss, and accounted for multiple factors, including the patient’s aPL profile, conventional cardiovascular risk 
factors, autoimmune antibody profile, and thromboprophylactic drug use [42]. The GAPSS can be calculated for 
each patient by adding the points corresponding to the different risk factors, weighted as shown. GAPSS values ≥10 
have demonstrated the best diagnostic accuracy compared with the different thresholds for APS diagnosis. 
 
Conclusions 
Although some controversial data exist, most of the studies in the literature support the association between 
antibodies directed to prothrombin, particularly aPS/PT, and the clinical manifestations of the APS. In addition, the 
correlation with the LA make these antibodies an interesting subpopulation in APS. Many groups are currently 
working towards further characterisation of aPS/PT and their mechanisms of action, although additional laboratory 
and clinical studies are needed to conclusively define the relevance and prognosis impact of testing for these 
antibodies in the daily routine clinical practise. The possibility of antiprothrombin antibodies, particularly aPS/PT, 
becoming an additional serological classification criterion for APS is being eagerly discussed, especially when 
considering how to identify APS patients negative for classical aPL. 
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Fig. 1 
Schematic structure of the prothrombin molecule. Cleavage at Arg273-Thr274 results in the liberation of 
prothrombin fragment 1 + 2 (residues 1–273) and prethrombin 2 (residues 274–581); further cleavage at Arg322-
Ile323 results in the formation of α-thrombin 
 
 
Fig. 2 
ELISA systems for the detection of antiprothrombin antibodies. Antibodies are unable to bind prothrombin when 
prothrombin is immobilised onto non-irradiated plates (a), but they bind when prothrombin is immobilised on a 
suitable anionic surface, adsorbed on gamma-irradiated plates (b) or exposed to immobilised anionic 
phospholipid (c) 
 
 
Table 1 
The Global AntiPhospholipid Syndrome Score (GAPSS) 
 
Factor Point value 
Anticardiolipin IgG/IgM 5 
Anti-β2-glycoprotein IgG/IgM 4 
Lupus anticoagulant 4 
Anti-prothrombin/phosphatidylserine complex (aPS/PT) IgG/IgM 3 
Hyperlipidemia 3 
Arterial hypertension 1 
   
 
 
